Dr. Alejandro Dorenbaum, M.D. - Chief Medical Officer, Reneo Pharmaceuticals - Developing Novel Therapies For Patients With Rare Genetic Mitochondrial Diseases

Dr. Alejandro (Alex) Dorenbaum, M.D., is the Chief Medical Officer of Reneo Pharmaceuticals ( https://reneopharma.com/ ), a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic diseases, including mitochondrial diseases, with significant unmet medical needs. Previously, Dr. Dorenbaum was Chief Medical Officer at Allakos, where he achieved proof-of-concept in clinical trials for novel therapeutic antibodies targeting inflammatory cells. He also served as Chief Medical Officer at Lumena Pharmaceuticals until its acquisition by Shire Pharmaceuticals. Prior to that, Dr. Dorenbaum worked at Genentech, where he was responsible for the respiratory programs for asthma and cystic fibrosis, and at BioMarin Pharmaceutical, where he conducted the clinical development of Kuvan. He began his career at Chiron Corporation, gaining broad expertise in several areas of drug development including biologics, small molecules and vaccines. Dr. Dorenbaum received his M.D. from the National Autonomous University in Mexico City. He completed his residency in pediatrics at University of Texas Health Science Center and held a fellowship in allergy and immunology at Baylor College of Medicine. He maintains an active academic position as Clinical Professor in Pediatrics at Stanford University School of Medicine, where he specializes in allergy and immunology. 

Support the Show.